These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35491653)

  • 1. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
    Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
    Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
    Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    van Harten AM; Poell JB; Buijze M; Brink A; Wells SI; René Leemans C; Wolthuis RMF; Brakenhoff RH
    Oral Oncol; 2019 Nov; 98():53-61. PubMed ID: 31541927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing.
    Chung CH; Guthrie VB; Masica DL; Tokheim C; Kang H; Richmon J; Agrawal N; Fakhry C; Quon H; Subramaniam RM; Zuo Z; Seiwert T; Chalmers ZR; Frampton GM; Ali SM; Yelensky R; Stephens PJ; Miller VA; Karchin R; Bishop JA
    Ann Oncol; 2015 Jun; 26(6):1216-1223. PubMed ID: 25712460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutations in head and neck cancer.
    Nathan CA; Khandelwal AR; Wolf GT; Rodrigo JP; Mäkitie AA; Saba NF; Forastiere AA; Bradford CR; Ferlito A
    Mol Carcinog; 2022 Apr; 61(4):385-391. PubMed ID: 35218075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive genomic profiling of penile squamous cell carcinoma and the impact of human papillomavirus status on immune-checkpoint inhibitor-related biomarkers.
    Nazha B; Zhuang T; Wu S; Brown JT; Magee D; Carthon BC; Kucuk O; Nabhan C; Barata PC; Heath EI; Ryan CJ; McKay RR; Master VA; Bilen MA
    Cancer; 2023 Dec; 129(24):3884-3893. PubMed ID: 37565840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
    Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
    Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program.
    Doerstling S; Winski D; Katsoulakis E; Agarwal P; Poonnen PJ; Snowdon JL; Jackson GP; Weeraratne D; Kelley MJ; Vashistha V
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):69-77. PubMed ID: 36117189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 11q13 amplification status and human papillomavirus in relation to p16 expression defines two distinct etiologies of head and neck tumours.
    Ragin CC; Taioli E; Weissfeld JL; White JS; Rossie KM; Modugno F; Gollin SM
    Br J Cancer; 2006 Nov; 95(10):1432-8. PubMed ID: 17003776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
    Xing D; Fadare O
    Semin Diagn Pathol; 2021 Jan; 38(1):50-61. PubMed ID: 33032902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines.
    Nichols AC; Yoo J; Palma DA; Fung K; Franklin JH; Koropatnick J; Mymryk JS; Batada NN; Barrett JW
    Arch Otolaryngol Head Neck Surg; 2012 Aug; 138(8):732-9. PubMed ID: 22911296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.
    Seiwert TY; Zuo Z; Keck MK; Khattri A; Pedamallu CS; Stricker T; Brown C; Pugh TJ; Stojanov P; Cho J; Lawrence MS; Getz G; Brägelmann J; DeBoer R; Weichselbaum RR; Langerman A; Portugal L; Blair E; Stenson K; Lingen MW; Cohen EE; Vokes EE; White KP; Hammerman PS
    Clin Cancer Res; 2015 Feb; 21(3):632-41. PubMed ID: 25056374
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Cao CH; Liu R; Lin XR; Luo JQ; Cao LJ; Zhang QJ; Lin SR; Geng L; Sun ZY; Ye SK; Yu ZY; Shi Y; Xia X
    Int J Biol Sci; 2021; 17(7):1744-1756. PubMed ID: 33994859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner.
    Pifer PM; Yang L; Kumar M; Xie T; Frederick M; Hefner A; Beadle B; Molkentine D; Molkentine J; Dhawan A; Abdelhakiem M; Osman AA; Leibowitz BJ; Myers JN; Pickering CR; Sandulache VC; Heymach J; Skinner HD
    Clin Cancer Res; 2024 Jan; 30(1):187-197. PubMed ID: 37819945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p16, p53 and EGFR expression in head and neck squamous cell carcinoma and their correlation with clinicopathological parameters.
    Gupta S; Pandey P; Verma S; Verma A
    J Cancer Res Ther; 2024 Apr; 20(3):881-887. PubMed ID: 39023595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.